News
Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.
1h
Zacks Investment Research on MSNBAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...
Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside.
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results